Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia

Ayumi Fujimoto, Fumihiro Ishida, Koji Izutsu, Satoshi Yamasaki, Dai Chihara, Junji Suzumiya, Tetsuo Mitsui, Noriko Doki, Hitoshi Sakai, Hikaru Kobayashi, Junya Kanda, Takahiro Fukuda, Yoshiko Atsuta, Ritsuro Suzuki

研究成果: ジャーナルへの寄稿学術誌査読

4 被引用数 (Scopus)


Aggressive NK-cell leukemia (ANKL) has a fulminant clinical course with a poor prognosis. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment. Using the Japanese transplant registry data, the outcomes of 59 ANKL patients who underwent first allo-HSCT were analyzed. Twenty-nine patients received stem cells from cord blood (CB), 18 from peripheral blood, and 12 from bone marrow. At the time of transplant 21 patients had complete response (CR), and 7 partial response (PR), but 31 without response. The 1-year and 5-year overall survival (OS) were 33.9% and 27.3%, respectively. The 1-year cumulative incidences of relapse or progression was 55.5%, and that of non-relapse mortality was 12.1%. The OS was significantly better for patients with CR or PR at the time of allo-HSCT (P = 0.046), which was equivalent to that for patients who experienced primary induction failure at the time of allo-HSCT but achieved CR afterwards (40.6% versus 32.0% at 5 years; P = 0.95). Patients receiving CB had a significantly better OS than those receiving stem cells from others (37.3% versus 16.2% at 5 years; P = 0.04). Patients achieving event-free survival at 12 months after allo-HSCT had good outcomes with 5-year OS of 85.2%.

ジャーナルBone Marrow Transplantation
出版ステータス出版済み - 2月 2021

!!!All Science Journal Classification (ASJC) codes

  • 血液学
  • 移植


「Allogeneic stem cell transplantation for patients with aggressive NK-cell leukemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。